The global hospital acquired pneumonia drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to accelerate the growth of the market include increasing risk factors with longer hospital stays. Pneumonia is a leading cause of death across the globe with a fatality rate of 4-10%. Hospital-acquired pneumonia is the most common form among the others and it has a huge impact on the lifestyle of the patient. Further, it is associated with a high mortality rate and requires immediate medical intervention. Owing to this, there is a huge demand for pharmacological intervention for effective management of the disease. According to Infectious Control and Epidemiology, the overall incidence in the US is 1.6% and represents 3.63 per 1000 patients. Increasing prevalence among the healthcare settings led to the potential growth of the market.
To Request a Sample of our Report on Global Hospital Acquired Pneumonia Drugs Market: https://www.omrglobal.com/request-sample/hospital-acquired-pneumonia-drugs-market
Hospital-acquired pneumonia is acquired by patients after they are being admitted to the hospital for more than 48 hours. The public healthcare system is facing a tough challenge in the form of hospital-acquired pneumonia as it is the second most common hospital-acquired infection. Pneumonia causes agitation of the lungs and mainly affects the alveoli which are microscopic air sacs. Primary causes of hospital-acquired pneumonia are bacteria or viral infections and they can be differentiated based on how the infection was acquired by the patient. In order to maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships and collaborations, and mergers and acquisitions. For instance, in July 2019, Bayer Healthcare partnered with Cubist pharmaceutical Inc. and co-developed Sivextro, an antibiotic for hospital-acquired pneumonia treatment.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Merck & Co., Inc., Pfizer Inc, and GlaxoSmithKline plc, among others.
A full Report of Global Hospital Acquired Pneumonia Drugs Market is Available @ https://www.omrglobal.com/industry-reports/hospital-acquired-pneumonia-drugs-market
Global Hospital Acquired Pneumonia Drugs Market Report by Segment
By Type
- Antibacterial
- Antiviral
- Antifungal
By Application
- Hospitals
- Clinics
- Others
Global Hospital Acquired Pneumonia Drugs Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hospital-acquired-pneumonia-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
